Skip to main content

Table 2 Base-case results from the Markov model, based on 5000 simulations

From: Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

 

Crizotinib Arm

Chemotherapy Arm

Incremental

COSTS

$288,945

$78,071

$210,874

 Testing

$7215

$0

$7215

 PFS - First line

$246,127

$31,218

$214,909

 Progressed - Second line

$11,879

$22,894

-$11,015

 Progressed - Third line

$12,345

$13,959

-$1614

 Palliation

$11,379

$10,001

$1379

LIFE YEARS (LYs)

3.349

2.465

0.885

 PFS - First line

2.256

1.735

0.521

 Progressed - Second line

0.680

0.288

0.392

 Progressed - Third line

0.155

0.175

−0.020

 Palliation

0.258

0.267

−0.009

QALYS

2.541

1.769

0.772

 PFS - First line

1.819

1.337

0.482

 Progressed - Second line

0.449

0.190

0.259

 Progressed - Third line

0.102

0.115

−0.013

 Palliation

0.170

0.126

0.044

ICER (Cost per LY gained)

 

$238,394

ICER (Cost per QALY gained)

 

$273,286

  1. ICER Incremental cost effectiveness ratio, PFS Progression-free survival, QALY Quality adjusted life year